Telo Genomics Corp, formerly 3D Signatures Inc, is a Canada-based personalized medicine company with a software platform based on the three-dimensional (3D) analysis of telomere organization. Its TeloViewTM platform is designed to inform clinicians and patients with respect to how to personalize treatment and manage an individual’s disease based on their TeloViewTM score. Its software-based technology and prognostic methodology target various diseases that demonstrate genomic instability, including cancer and neurological disorders. It is engaged in developing over five diagnostic and prognostic products for cancers and neurological disorders, including TELO-HL, Telo-MM, Telo-PC, Telo-LC and Telo-AD. Its Telo-PC enables clinicians to identify patient stability during diagnosis, optimize treatment plans and manage to monitor with a non-invasive blood test. Its technology analyzes a specific part of an individual’s deoxyribonucleic acid to determine how a disease progress.